Article thumbnail

Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells

By Monika Raab, Sven Kappel, Andrea Krämer, Mourad Sanhaji, Yves Matthess, Elisabeth Kurunci-Csacsko, Julia Calzada-Wack, Birgit Rathkolb, Jan Rozman, Thure Adler, Dirk H. Busch, Irene Esposito, Helmut Fuchs, Valérie Gailus-Durner, Martin Klingenspor, Eckhard Wolf, Nicole Sänger, Florian Prinz, Martin Hrabě de Angelis, Jost Seibler, Juping Yuan, Martin Bergmann, Rainald Knecht, Bertolt Kreft and Klaus Strebhardt


High attrition rates of novel anti-cancer drugs highlight the need for improved models to predict toxicity. Although polo-like kinase 1 (Plk1) inhibitors are attractive candidates for drug development, the role of Plk1 in primary cells remains widely unexplored. Therefore, we evaluated the utility of an RNA interference-based model to assess responses to an inducible knockdown (iKD) of Plk1 in adult mice. Here we show that Plk1 silencing can be achieved in several organs, although adverse events are rare. We compared responses in Plk1-iKD mice with those in primary cells kept under controlled culture conditions. In contrast to the addiction of many cancer cell lines to the non-oncogene Plk1, the primary cells' proliferation, spindle assembly and apoptosis exhibit only a low dependency on Plk1. Responses to Plk1-depletion, both in cultured primary cells and in our iKD-mouse model, correspond well and thus provide the basis for using validated iKD mice in predicting responses to therapeutic interventions

Topics: Article
Publisher: Nature Publishing Group
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1988). a mitotic mutant of Drosophila displaying abnormal spindle poles.
  2. (2000). All you wanted to know about spermatogonia but were afraid to ask.
  3. (1996). Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.
  4. (2006). Assessing iron status: beyond serum ferritin and transferrin saturation.
  5. (2007). BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
  6. (2008). Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs.
  7. (2004). Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.
  8. (2002). Cancer modeling in the modern era: progress and challenges.
  9. (2010). Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity.
  10. (2005). Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1.
  11. (2002). Cooperative phosphorylation including the activity of pololike kinase 1 regulates the subcellular localization of cyclin B1.
  12. (2001). Damaging effect of taxol on mouse spermatogenesis.
  13. (1994). Density-dependent inhibition of mouse embryo fibroblast growth: involvement of IGFBP-3.
  14. (1998). Drosophila polo kinase is required for cytokinesis.
  15. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.
  16. (1969). Duration of the cycle of the seminiferous epithelium in the mouse and hamster determined by means of 3H-thymidine and radioautography.
  17. (2002). Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells.
  18. (2008). Ehrlich’s magic bullet concept: 100 years of progress.
  19. (2006). From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research.
  20. (2000). Genetic and epigenetic changes in human epithelial cells immortalized by telomerase.
  21. (2008). Genetic influence on immune phenotype revealed strainspecific variations in peripheral blood lineages.
  22. (2010). Genetically engineered mouse models in cancer research.
  23. (1997). Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions.
  24. (2002). Identification of high risk breast-cancer patients by gene expression profiling.
  25. (2005). Introducing the German Mouse Clinic: open access platform for standardized phenotyping.
  26. (2009). Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle 8,
  27. (2010). Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.
  28. (2006). Normal cells, but not cancer cells, survive severe Plk1 depletion.
  29. (2008). Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
  30. (1997). Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures.
  31. (2008). Polo on the rise-from mitotic entry to Cytokinesis with Plk1.
  32. (2008). Polo-like kinase 1 is essential for early embryonic development and tumor suppression.
  33. (1997). Polo-like kinase, a novel marker for cellular proliferation.
  34. (2005). Polo-like kinases and oncogenesis.
  35. (2004). Polo-like kinases and the orchestration of cell division.
  36. (2009). Polo-like kinases: conservation and divergence in their functions and regulation.
  37. (2007). Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
  38. (2007). Reversible gene knockdown in mice using a tight, inducible shRNA expression system.
  39. (2010). Shared and separate functions of polo-like kinases and aurora kinases in cancer.
  40. (2007). Silencing of mammalian genes by tetracycline-inducible shRNA expression.
  41. (2005). Single copy shRNA configuration for ubiquitous gene knockdown in mice.
  42. (2005). Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
  43. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint.
  44. (2010). T cell receptor ‘inside-out’ pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes.
  45. (2007). Targeted anti-mitotic therapies: can we improve on tubulin agents?
  46. (2006). Targeting polo-like kinase 1 for cancer therapy.
  47. (2008). Targeting polo-like kinase: learning too little too late?
  48. (2006). The mighty mouse: genetically engineered mouse models in cancer drug development.
  49. (2010). The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. PLoS One 5,
  50. (1998). The POLO kinase is required at multiple stages during spermatogenesis in Drosophila melanogaster.
  51. (2001). The polo-like kinase Plx1 is required for activation of the phosphatase Cdc25C and cyclin B-Cdc2 in Xenopus oocytes.
  52. (2007). The spindle-assembly checkpoint in space and time.